» Articles » PMID: 38433266

Somatic CAG Repeat Instability in Intermediate Alleles of the HTT Gene and Its Potential Association with a Clinical Phenotype

Overview
Journal Eur J Hum Genet
Specialty Genetics
Date 2024 Mar 3
PMID 38433266
Authors
Affiliations
Soon will be listed here.
Abstract

Huntington disease (HD) is a neurodegenerative disorder caused by ≥36 CAGs in the HTT gene. Intermediate alleles (IAs) (27-35 CAGs) are not considered HD-causing, but their potential association with neurocognitive symptoms remains controversial. As HTT somatic CAG expansion influences HD onset, we hypothesised that IAs are somatically unstable, and that somatic CAG expansion may drive phenotypic presentation in some IA carriers. We quantified HTT somatic CAG expansions by MiSeq sequencing in the blood DNA of 164 HD subjects and 191 IA (symptomatic and control) carriers, and in the brain DNA of a symptomatic 33 CAG carrier. We also performed genotype-phenotype analysis. The phenotype of symptomatic IA carriers was characterised by motor (85%), cognitive (27%) and/or behavioural (29%) signs, with a late (58.7 ± 18.6 years), but not CAG-dependent, age at onset. IAs displayed somatic expansion that were CAG and age-dependent in blood DNA, with 0.4% and 0.01% of DNA molecules expanding by CAG and year, respectively. Somatic expansions of +1 and +2 CAGs were detected in the brain of the individual with 33 CAGs, with the highest expansion frequency in the putamen (10.3%) and the lowest in the cerebellum (4.8%). Somatic expansion in blood DNA was not different in symptomatic vs. control IA carriers. In conclusion, we show that HTT IAs are somatically unstable, but we found no association with HD-like phenotypes. It is plausible, however, that some IAs, close to the HD pathological threshold and with a predisposing genetic background, could manifest with neurocognitive symptoms.

Citing Articles

Natural Products and Their Neuroprotective Effects in Degenerative Brain Diseases: A Comprehensive Review.

Lim D, Lee J, Lee C, Kim Y Int J Mol Sci. 2024; 25(20).

PMID: 39457003 PMC: 11508681. DOI: 10.3390/ijms252011223.


Hitting the heights with CiteScore.

McNeill A Eur J Hum Genet. 2024; 32(7):743-744.

PMID: 38956180 PMC: 11219711. DOI: 10.1038/s41431-024-01651-6.


Comment on: "Somatic CAG repeat instability in intermediate alleles of the HTT gene and its potential association with a clinical phenotype" by Ruiz de Sabando et al.

Mroczek M Eur J Hum Genet. 2024; 32(7):745-746.

PMID: 38448560 PMC: 11219756. DOI: 10.1038/s41431-024-01587-x.

References
1.
Rosas I, Martinez C, Clarimon J, Lleo A, Illan-Gala I, Dols-Icardo O . Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Neurobiol Aging. 2019; 87:139.e1-139.e7. DOI: 10.1016/j.neurobiolaging.2019.10.017. View

2.
Gomes-Pereira M, Bidichandani S, Monckton D . Analysis of unstable triplet repeats using small-pool polymerase chain reaction. Methods Mol Biol. 2004; 277:61-76. DOI: 10.1385/1-59259-804-8:061. View

3.
Herishanu Y, Parvari R, Pollack Y, Shelef I, Marom B, Martino T . Huntington disease in subjects from an Israeli Karaite community carrying alleles of intermediate and expanded CAG repeats in the HTT gene: Huntington disease or phenocopy?. J Neurol Sci. 2008; 277(1-2):143-6. DOI: 10.1016/j.jns.2008.11.005. View

4.
Squitieri F, Esmaeilzadeh M, Ciarmiello A, Jankovic J . Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG(33) repeat length in the Huntington's disease gene. Mov Disord. 2011; 26(5):925-7. DOI: 10.1002/mds.23623. View

5.
Shelbourne P, Keller-McGandy C, Bi W, Yoon S, Dubeau L, Veitch N . Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain. Hum Mol Genet. 2007; 16(10):1133-42. DOI: 10.1093/hmg/ddm054. View